Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

AMSBIO Launches Comprehensive Selection of Products for Wnt Signaling Research

05 October 2016: Abingdon, UK - AMSBIO has launched a comprehensive selection of products for Wnt signaling research including recombinant proteins, stable reporter cell lines, polyclonal antibodies and ELISA assay kits.

Read the rest of entry »

Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement for European Rights to Summit's Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

04 October 2016: Oxford, UK & Cambridge, USA - Sarepta Therapeutics and Summit Therapeutics plc today announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States ('the licensed territory'), to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy ('DMD'). As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summit's utrophin modulator pipeline. Summit retains commercialization rights in all other countries.

Read the rest of entry »

Healx Secures £1.5m from Amadeus Capital and Investors to Combat Rare Diseases

04 October 2016: Cambridge, UK – Healx, an innovative British healthcare company that seeks new uses for existing drugs in the fight against rare diseases has secured an early-stage investment from Amadeus Capital Partners, the global technology investor. Amadeus Capital is investing in a £1.5 million Series A round, alongside renowned healthcare entrepreneur, Jonathan Milner. Board members include bio-tech entrepreneur, Darrin Disley, and drug development leader, David Brown, co-inventor of Viagra.

Read the rest of entry »

Wickham Laboratories Announces Upcoming Webinar on Microbial Limits Testing

04 October 2016: Gosport UK - Join Wickham Laboratories for a Free Webinar on Risks, Regulations and Determining the Best Method for Your Product, 3rd November, 3PM GMT.

Read the rest of entry »

EUSA Pharma Acquires Global Rights to Neuroblastoma Treatment Isqette® (dinutuximab beta) from Apeiron Biologics

04 October 2016: Hemel Hempstead, UK & Vienna, Austria – EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of exclusive global commercialization rights to the oncology product Isqette (dinutuximab beta) from Apeiron Biologics.

Read the rest of entry »

Oxford Immunotec Announces Favorable Decision from U.S. District Court of Massachusetts in Patent Infringement Litigation

03 October 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that the U.S. District Court for the District of Massachusetts reinstated the kit claims of the Company’s patent infringement claims against the defendants, Qiagen, Inc., Quest Diagnostics Inc. and Laboratory Corporation of America Holdings, following its review of the Magistrate Judge’s Report and Recommendation of August 31, 2016.

Read the rest of entry »

MEPC Gets Green Light for UK’s First New Office and Laboratory Development Since the EU Referendum

03 October 2016: Abingdon, UK - MEPC has secured planning consent at Milton Park in Oxfordshire for the first speculative office and laboratory development to be submitted and approved in the UK since the EU Referendum in June. As a result, MEPC will be pressing the button to build three new high specification buildings totalling 110,000 sq ft, which will be completed by late 2017.

Read the rest of entry »

Chancellor Announces £220 million for Cutting-edge New Technology

01 October 2016: London, UK - Philip Hammond has today (1 October 2016) unveiled a package of support which includes £220 million for the life science and university sectors to help technology breakthroughs translate into commercial success, as well as action to ensure disruptive businesses thrive in the UK.

Read the rest of entry »

PCI Pharma Services Welcomes Jens Peter Nielsen as Business Development Manager at its Hay-on-Wye, UK Site

29 September 2016: Hay on Wye, UK – Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Jens Peter Nielsen as Business Development Manager in its European commercial packaging team, which includes its Hay-on-Wye site in Wales, UK, and a recognized center of excellence for packaging, one of four locations in Europe.

Read the rest of entry »

Sareum Announce Licence agreement for Chk1 Inhibitor CCT245737

27 September 2016: Cambridge, UK - Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that its co-investment partner, the CRT Pioneer Fund, has today licensed exclusive and worldwide rights for the Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) to ProNAi Therapeutics, Inc. (NASDAQ: DNAI).

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.